159 related articles for article (PubMed ID: 15530861)
1. In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Pasco S; Ramont L; Venteo L; Pluot M; Maquart FX; Monboisse JC
Exp Cell Res; 2004 Dec; 301(2):251-65. PubMed ID: 15530861
[TBL] [Abstract][Full Text] [Related]
2. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
[TBL] [Abstract][Full Text] [Related]
3. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Floquet N; Pasco S; Ramont L; Derreumaux P; Laronze JY; Nuzillard JM; Maquart FX; Alix AJ; Monboisse JC
J Biol Chem; 2004 Jan; 279(3):2091-100. PubMed ID: 14583633
[TBL] [Abstract][Full Text] [Related]
4. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
5. Expression, purification, and bioactivity of human tumstatin from Escherichia coli.
Gu Q; Zhang T; Luo J; Wang F
Protein Expr Purif; 2006 Jun; 47(2):461-6. PubMed ID: 16503164
[TBL] [Abstract][Full Text] [Related]
6. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
7. A new anti-tumor strategy based on in vivo tumstatin overexpression after plasmid electrotransfer in muscle.
Thevenard J; Ramont L; Mir LM; Dupont-Deshorgue A; Maquart FX; Monboisse JC; Brassart-Pasco S
Biochem Biophys Res Commun; 2013 Mar; 432(4):549-52. PubMed ID: 23454380
[TBL] [Abstract][Full Text] [Related]
8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
9. The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration.
Thevenard J; Ramont L; Devy J; Brassart B; Dupont-Deshorgue A; Floquet N; Schneider L; Ouchani F; Terryn C; Maquart FX; Monboisse JC; Brassart-Pasco S
Int J Cancer; 2010 Mar; 126(5):1055-66. PubMed ID: 19551865
[TBL] [Abstract][Full Text] [Related]
10. Control of melanoma cell invasion by type IV collagen.
Pasco S; Brassart B; Ramont L; Maquart FX; Monboisse JC
Cancer Detect Prev; 2005; 29(3):260-6. PubMed ID: 15936594
[TBL] [Abstract][Full Text] [Related]
11. Beta-carotene inhibits tumor-specific angiogenesis by altering the cytokine profile and inhibits the nuclear translocation of transcription factors in B16F-10 melanoma cells.
Guruvayoorappan C; Kuttan G
Integr Cancer Ther; 2007 Sep; 6(3):258-70. PubMed ID: 17761639
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9.
Bianchini F; D'Alessio S; Fibbi G; Del Rosso M; Calorini L
Oncol Rep; 2006 Mar; 15(3):709-14. PubMed ID: 16465434
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid.
Ahrens T; Sleeman JP; Schempp CM; Howells N; Hofmann M; Ponta H; Herrlich P; Simon JC
Oncogene; 2001 Jun; 20(26):3399-408. PubMed ID: 11423990
[TBL] [Abstract][Full Text] [Related]
14. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth.
Trisciuoglio D; Desideri M; Ciuffreda L; Mottolese M; Ribatti D; Vacca A; Del Rosso M; Marcocci L; Zupi G; Del Bufalo D
J Cell Physiol; 2005 Dec; 205(3):414-21. PubMed ID: 15920759
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix.
Mimura K; Sueishi K; Yasunaga C; Tanaka K
Invasion Metastasis; 1992; 12(1):24-34. PubMed ID: 1380952
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice.
Chijiwa T; Abe Y; Ikoma N; Yamazaki H; Tsukamoto H; Suemizu H; Kawai K; Wakui M; Nishime C; Matsumoto H; Matsuyama M; Mukai M; Ueyama Y; Nakamura M
Int J Oncol; 2009 Jan; 34(1):5-13. PubMed ID: 19082472
[TBL] [Abstract][Full Text] [Related]
18. NGR enhanced the anti-angiogenic activity of tum-5.
Meng J; Ma N; Yan Z; Han W; Zhang Y
J Biochem; 2006 Aug; 140(2):299-304. PubMed ID: 16845126
[TBL] [Abstract][Full Text] [Related]
19. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.
Hamano Y; Kalluri R
Biochem Biophys Res Commun; 2005 Jul; 333(2):292-8. PubMed ID: 15979458
[TBL] [Abstract][Full Text] [Related]
20. Structural and antitumor properties of the YSNSG cyclopeptide derived from tumstatin.
Thevenard J; Floquet N; Ramont L; Prost E; Nuzillard JM; Dauchez M; Yezid H; Alix AJ; Maquart FX; Monboisse JC; Brassart-Pasco S
Chem Biol; 2006 Dec; 13(12):1307-15. PubMed ID: 17185226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
